Month: February 2021

Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2021 Financial Results and Recent Business Highlights

— Positive Results from Phase 2 Clinical Study of PL9643 in Patients with Dry Eye Disease — Continue to Rebuild Commercial Infrastructure and Brand Awareness for Vyleesi® — Approximately $72.2 Million in Cash and Cash Equivalents at December 31, 2020 — Teleconference and Webcast to be held on February 17, 2021 at 11:00 AM ET …

Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2021 Financial Results and Recent Business Highlights Read More »

Palatin Technologies, Inc. to Report Second Quarter, Fiscal Year 2021 Results; Teleconference and Webcast to be held on February 17, 2021

Feb 12, 2021, 07:30 ET CRANBURY, N.J., Feb. 12, 2021 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) will announce its second quarter, fiscal year 2021 operating results on Wednesday, February 17, 2021 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its …

Palatin Technologies, Inc. to Report Second Quarter, Fiscal Year 2021 Results; Teleconference and Webcast to be held on February 17, 2021 Read More »

Palatin Technologies Announces Filing of International Patent Application Claiming PL9643

Application Could Provide U.S. and International Patent Coverage for PL9643, Palatin’s Lead Compound for Dry Eye Disease Phase 2/3 Clinical Trial Currently Planned for Mid-2021 Feb 10, 2021, 07:30 ET CRANBURY, N.J., Feb. 10, 2021 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the …

Palatin Technologies Announces Filing of International Patent Application Claiming PL9643 Read More »

Scroll to Top